Dengue Vaccination in Children and Adolescents: Current Evidence, Safety, and Future Directions
Vaccines · 15.11.2026 · 14 (11) · 983
DOI: 10.3390/vaccines14110983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.11.2026. Verfasst von Marco Masetti und 2 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Dengue is an expanding mosquito-borne disease and a growing global health threat. Its four serotypes, changing epidemiology, and complex immune responses make vaccine development particularly challenging. This review examines dengue vaccines, with emphasis on children and adolescents.
Methods
PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library were searched from inception through 10 November 2026. Clinical trials, observational studies, reviews, surveillance reports, and guidelines addressing dengue immunopathogenesis, vaccine development, efficacy, immunogenicity, safety, effectiveness, or implementation were considered. Evidence was assessed with attention to pediatric populations, age, baseline serostatus, infecting serotype, and duration of protection.
Results
CYD-TDV provides moderate protection, but long-term follow-up identified an increased risk of hospitalized or severe dengue in seronegative recipients, making pre-vaccination screening central to its use. TAK-003 protects children and adolescents against virologically confirmed and hospitalized dengue, although efficacy varies by serotype and serostatus; protection against DENV-3 and DENV-4 in seronegative recipients remains uncertain. Butantan-DV showed efficacy across pediatric age groups and baseline serostatus, although the absence of DENV-3 and DENV-4 cases precluded serotype-specific estimates. Over five years, phase III rates of unsolicited vaccine-related adverse events, including serious events, were comparable with placebo. After ANVISA registered the vaccine for ages 12–59 on 8 December 2025, Brazil paused its vaccination strategy in June 2026 while investigating 42 reports following approximately 500,000 doses, including three severe cases and two deaths. Causality has not been established. TV003/TV005 and other platforms broaden the pipeline, though pediatric efficacy evidence remains limited. No validated correlate of protection is available. Affordability, equitable access, surveillance, and caregiver confidence remain important implementation challenges.
Conclusions
Dengue vaccines mark important progress, but their benefits and risks depend on age, serostatus, and circulating serotypes. Long-term, serotype-specific evaluation and post-marketing surveillance are needed. Next-generation vaccines, clear communication, and sustainable access will be essential to achieve durable, equitable protection for children.
Zitieren
APA
Masetti, M., Zambelli, G., & Esposito, S. (2026). Dengue Vaccination in Children and Adolescents: Current Evidence, Safety, and Future Directions. Vaccines, 14(11), 983. https://doi.org/10.3390/vaccines14110983
Vancouver
Masetti M, Zambelli G, Esposito S. Dengue Vaccination in Children and Adolescents: Current Evidence, Safety, and Future Directions. Vaccines. 2026;14(11):983. doi:10.3390/vaccines14110983
BibTeX
@article{Masetti2026,
author = {Masetti, Marco and Zambelli, Giulia and Esposito, Susanna},
title = {Dengue Vaccination in Children and Adolescents: Current Evidence, Safety, and Future Directions},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {983},
doi = {10.3390/vaccines14110983}
}
EUVIMED